NAD+ blood tests: what does a result mean?

Start with the sample and the method

NAD+ research does not use one interchangeable measurement. Studies can examine whole blood, plasma, urine metabolites or tissue. The Conze NR trial reported whole-blood NAD+, while the Grant IV pilot examined plasma and urine metabolites. Their numbers address different samples and study questions. They should not be placed on one consumer chart as though they were the same test.

Before comparing results, ask for the analyte name, sample type, units and assay method. Ask how the sample is handled and which laboratory performs the analysis. These details allow a clinician to judge what the measurement can support. An impressive percentage change is less informative when the report leaves the basic measurement unclear.

Reference ranges are not personal treatment instructions

A reference interval describes a comparison population under specified conditions. A treatment target needs additional justification. Ask how the laboratory developed its interval, whether it applies to your circumstances and whether a result outside it is connected to an established clinical decision. The word optimal can conceal those missing steps when it appears only in marketing copy.

Do not assume that higher must mean better. To support a target, researchers would need evidence connecting the measurement to an outcome and showing that acting on the result helps. A seller's chart can describe an association without proving that changing the chart's number improves a person's symptoms or future health.

Why two results can be difficult to compare

A before-and-after comparison is easiest to interpret when the laboratory, method, sample type and relevant collection conditions are consistent. If those change, the difference can reflect more than an intervention. Ask the laboratory or clinician what variation to expect and how they determine whether a change is meaningful.

The timing of a measurement also matters to the question being asked. A study measuring metabolites around an infusion is investigating an exposure-related response. It is not measuring the same thing as whether a symptom remains improved months later. The test should be chosen for a clinical or research question, rather than the question being invented to sell the test.

Does the result explain how you feel?

A laboratory result and a symptom can coexist without one explaining the other. If you are tired, have trouble concentrating or feel less able to exercise, a single NAD+ result cannot establish the cause on its own. A clinician needs the broader history and context. Avoid a purchasing funnel that labels a symptom as a deficiency before that assessment happens.

Evidence that a supplement changes a measured marker is also separate from evidence that testing everyone improves care. A clinically useful testing strategy needs a decision attached to the result and evidence that the decision helps. That is the question to bring to a testing service, particularly when it also sells the proposed treatment.

Questions to ask before paying

Ask what will happen with a low, middle or high result. If every result leads to the same subscription, the test may add little to the decision. Ask whether the report can be shared with your own clinician and whether the service explains the limits of the assay. A transparent answer is more useful than a promise to optimize an unspecified number.

Compare the full cost of the package, including repeat tests and consultations, rather than the introductory laboratory price alone. Decide what you want to learn before placing an order. This article does not recommend a testing interval or a threshold for treatment; those decisions need an appropriate clinical context and evidence beyond a sales page.

• Which analyte, sample, units and assay are used?
• How was the reference interval established?
• Is a change larger than expected measurement variation?
• What clinical decision changes because of the result?

Sources and scope

These are selected studies and official sources relevant to the question above, rather than a systematic review of every published paper. A finding applies to the people, ingredient, route and outcomes studied. This guide provides education, not a diagnosis or medical advice. Discuss personal treatment decisions with a licensed clinician.

1. Conze D and 2 others, Safety and Metabolism of Long-term Administration of NIAGEN (Nicotinamide Riboside Chloride) in a Randomized, Double-Blind, Placebo-controlled Clinical Trial of Healthy Overweight Adults. Sci Rep, 2019. PubMed 31278280. Read the PubMed record
2. Grant R and 6 others, A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD. Front Aging Neurosci, 2019. PubMed 31572171. Read the PubMed record

Continue reading

• NAD+ biomarkers vs health benefits

  What a higher laboratory result can establish, and what still needs a meaningful clinical outcome.

• NAD+ for energy and fatigue

  Read the fatigue and function outcomes behind energy claims, with the placebo comparisons kept in view.

• NR vs NMN vs NAD+

  The ingredient and route matter as much as the label. How human studies of precursors differ from studies of NAD+ itself.

All NAD+ research guides